Abstract
Abstract
Objectives
To assess sex-based differences in response to bimekizumab in patients with axial spondyloarthritis (axSpA) from two phase 3 trials.
Methods
Improvements to week 52 in measures of disease activity (ASAS40, ASDAS
Results
While sex distribution was balanced in nr-axSpA (54.3% male), 72.3% of patients with r-axSpA were male. At week 16, bimekizumab-randomized male patients typically had better treatment responses vs placebo compared with female patients across ASAS40, ASDAS
Conclusion
Although male patients had earlier clinical responses to bimekizumab treatment, female patients demonstrated longer-term improvements in composite and patient-reported outcomes. Both sexes had substantial improvements in objective inflammation at week 16 and 52, despite baseline differences.
Trial registration
Clinicaltrials.gov; NCT03928704 and NCT03928743